On December 23, 2013, ATMI (ATMI) confirmed my prior analysis that they would sell or monetize their fast growing LifeScience division.(see article here)The press release stated: "ATMI has agreed to sell its LifeScience unit to Pall Corp. (PLL) in a deal worth $185M, after-tax proceeds will be $165M." The sale is part of ATMI's ongoing exploration of strategic alternatives. The assets of the LifeScience business include two Belgian sites and a shared facility in Minnesota.
In my prior analysis I used a year end 2014 target valuation of 220M for their LifeScience division, which would be worth about $7/sh. From the look of it, this deal was a good one for ATMI, The deal...
Only subscribers can access this article, which is part of the PRO research library covering 3,805 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: